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Abstract
Neuroinfections are a significant medical problem and can have serious health consequences for patients. Their outcome, if not
fatal, can be associated with permanent residual deficits. Cerebrospinal fluid (CSF) examination is commonly used for meningitis
confirmation. Fatty acids (FA) are precursors of lipid mediators with pharmacological activity. They actively modulate inflam-
mation as well as contribute to its resolution. Therefore the aim of this study was to determine the FA and selected
endocannabinoids (ECB) content in the CSF obtained from patients with bacterial (BM) and viral meningitis (VM) using
chromatographic techniques. A significantly lower level of saturated FAwas found in patients with BM and VM as compared
to controls. There was a significantly higher concentration of long-chain monounsaturated FA and polyunsaturated n-6 FA in the
CSF obtained from patients with neuroinfection. Moreover, a significant reduction of n-3 FA in CSF obtained from patients with
BM and VM was demonstrated. The highest amount of ECB was detected in the CSF of patients with VM: eicosapentaenoyl
ethanolamide (1.65 pg/mL), docosahexaenoyl ethanolamide (655.5 pg/mL) and nervonoyl ethanolamide (3.09 ng/mL). Results
indicate the participation of long-chain monounsaturated and polyunsaturated FA and their derivatives in the inflammatory
process and likely in the process of resolution of inflammation during neuroinfection. It seems that the determination of the
FA and ECB profile in CSF may be a valuable biomarker of health and may allow the development of new pharmacological
strategies, therapeutic goals and fatty acids supplementation necessary in the fight against inflammation of the central nervous
system.
Keywords Cerebrospinal fluid . Inflammation . Pathogenesis . Fatty acids . Endocannabinoids . Neuroinfections
Abbreviations
AA arachidonic acid
AJs adherent junctions
BBB blood–brain barier
BM bacterial meningitis
CNS central nervous system
CSF cerebro-spinal fluid
CRP C-reactive protein
DHA docosahexaenoic fatty acid
DHEA docosahexaenoyl ethanolamide
ECB endocannabinoids
EPA eicosapentaenoic fatty acid
EPEA eicosapentaenoyl ethanolamide
FA fatty acids
GOS Glasgow Outcome Scores
GSC Glasgow Coma Scale
MUFA monounsaturated fatty acids
NEA nervonoyl ethanolamide
PUFA polyunsaturated fatty acids
Q25 lower quartile
Q75 upper quartile
SFA saturated fatty acids
* Joanna Gdula-Argasińska
jargasinska@cm-uj.krakow.pl
1 Department of Infectious and Tropical Diseases, Jagiellonian
University Medical College, Krakow, Poland
2 Department of Radioligands, Faculty of Pharmacy, Jagiellonian
University Medical College, Medyczna 9, 30-688 Krakow, Poland
3 Chair of Toxicology, Faculty of Pharmacy, Jagiellonian University
Medical College, Krakow, Poland
4 Department of Hematology, Jagiellonian University Medical
College, Krakow, Poland
5 Department of Medicine, John Dempsey Hospital, University of
Connecticut, Farmington, CT, USA
Metabolic Brain Disease (2019) 34:331–339
https://doi.org/10.1007/s11011-018-0347-7
TJs tight junctions
VM viral meningitis
WBC white blood cells
Introduction
Despite progress in the prevention and treatment of infectious
diseases, central nervous system (CNS) infections are a per-
sistent problem in modern medicine. Neuroinfections account
for significant worldwide morbidity and mortality, and are
observed throughout the globe in every age group from neo-
nates to older adults. They are characterized by a variety of
symptoms ranging from fever and headaches to the most se-
rious consequences including increased intracranial pressure
and irreversible damage to the nervous system, which, if not
fatal, can be associated with permanent residual deficits
(Leibovitch and Jacobson 2016).
Fatty acids (FA) and their derivatives are important medi-
ators in the human immune system. The intensity of the in-
flammatory process is influenced by changes in the metabo-
lism of eicosanoids, endocannabinoids (ECB) and other lipid
mediators (Stillwell and Wassall 2003; Shaikh and Edidin
2008; Serhan and Petasis 2011; Calder 2016).
CNS is an isolated place for infection, protected by the
blood-brain barrier (BBB). The BBB provides structural as
well as functional protection by maintaining homeostasis of
the CNS microenvironment, protecting the nervous system
against harmful factors, and also allowing selective transport
of substances between blood and cerebro-spinal fluid (CSF).
The BBB is therefore a barrier to pathogens, but also creates
unique conditions for the operation of the host immune sys-
tem. Selective BBB permeability is associated with a different
structure of the capillary endothelium, forming a physical bar-
rier. Endothelial cells are connected with each other through
adherens junctions (AJs) and tight junctions (TJs), which have
no gaps or pores, therefore substances present in the plasma
can overcome the endothelium barrier only by means of trans-
cellular transport (Ballabh et al. 2004; Nakagawa et al. 2009;
van Sorge and Doran 2012).
The few studies of FA concentration in human CSF con-
cerned only cases of strokes and brain injuries (Pilitsis et al.
2001, 2003a, b). The concept of these studies resulted from
the previously shown significant increases of FA during path-
ological processes in nervous system, mainly ischemia in an-
imal studies (Yasuda et al. 1985; Abe et al. 1987; Yoshida
et al. 1980). Pilitsis et al. (2003a) assessed concentrations of
arachidonic, docosahexaenoic, linoleic, myristic, oleic and
palmitic acids in CSF from patients with ischemic and primary
intracerebral hemorrhagic stroke (Pilitsis et al. 2003a). The
concentrations of all studied FAwere significantly greater than
in control patients. Moreover, the higher concentration of
polyunsaturated fatty acids (PUFA) significantly correlated
with the worse Glasgow Coma Scale (GSC) score on admis-
sion and with the final outcome of stroke (Pilitsis et al. 2003a).
Similar results were obtained by the authors who compared
FA in people with traumatic brain injury compared to healthy
people, the concentrations of arachidonic, DHA, myristic,
oleic, palmitic, linoleic were significantly greater among pa-
tients with brain injury. There were no significant differences
in FA concentration depending on Glasgow Outcome Scores
(GOS), however, in patients who had early clinical improve-
ment, AA, DHA and linoleic acids were significantly lower
than in patients with worse outcome ratings. Pilitsis et al.
(2003b) suggested that concentrations of FA may be useful
as predictive markers of outcome in traumatic brain injury
patients (Pilitsis et al. 2003b). Similar results for FA after brain
injuries were observed in rat studies (Homayoun et al. 2000).
So far, the role of FA and their derivatives in the course of
infection has been demonstrated (Shaikh and Edidin 2008;
Tiesset et al. 2009; Czepiel et al. 2016), but there are no stud-
ies assessing this effect during neuroinfection. Moreover, the
concentration of FA and ECB in neuroinfections was never
directly assessed in the material taken from the CNS.
Taking this into account, the aim of our work was to assess
the FA and ECB content in CSF during various etiologies of
infection of the nervous system.
Materials and methods
Patients
The study group included 57 patients: 19 patients with bacte-
rial meningitis (BM) (6 women and 13 men), 19 patients with
viral meningitis (VM) (9 women and 10 men), and 19 patients
(8 women and 11 men) in whom meningitis was excluded,
who were hospitalized at the Department of Infectious and
Tropical Diseases, Jagiellonian University Hospital in
Krakow, Poland. All patients had signed a filled informed
consent to participate in the examination.
The diagnosis of meningitis was based on history, physical
examination and laboratory testing.Meningitis was confirmed
or excluded after CSF examination, in which cytosis and the
level of protein, glucose and white blood cells (WBC) were
assed. Blood tests included WBC with differential leukocyte
count and C-reactive protein (CRP), the tests were performed
according to generally accepted standard methods. Moreover,
each sample of CSF underwent microbiological assessment.
Exclusion criteria included any other acute or chronic inflam-
matory diseases. Samples from each group were obtained
from lumbar punctures for medically indicated reasons. All
samples came from CSF left over in the main laboratory.
Blood tests, demographic and clinical information were re-
corded using standardized data collection forms. The study
was conducted in accordance with the Declaration of
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Helsinki 1975, and approved by the Jagiellonian University
Ethics Committee (approval no 1072.6120.52.2018).
Lipid extraction
One mL of CSF were acidified with 50 μL of 0.01% formic
acid (Sigma-Aldrich, St. Louis, MO, USA). Ten microliter of
0.001% butylated dihydroxytoluene (BHT, Sigma-Aldrich)
was added to prevent lipid oxidation. Lipids were extracted
with chloroform–methanol solution (2:1 v/v) (Merck,
Darmstadt, Germany). Two microliters of internal standards
were used throughout: eicosapentaenoyl ethanolamide
(EPEA-d4) and docosahexaenoyl ethanolamide (DHEA-d4),
at concentration 10 μg/mL (Cayman Chemical, Ann Arbor,
MI, USA). Samples were vortexed for 30 s and centrifuged for
10 min at 1000 x g. Organic phases were collected and dried
under a stream of nitrogen. The residue was dissolved in
40 μL of acetonitrile (Merck).
Fatty acid analysis
The synthesis of fatty acid methyl esters (FAME) was carried
out with 14% BF3 in methanol. FAME were analyzed using
gas chromatography (Agilent 6890 N, Agilent Inc., Santa
Clara, CA, USA) with a J&W DB-23 (60 m, ID 0.25 mm,
0.25 μm) column, as described earlier (Gdula-Argasińska
et al. 2016; Gdula-Argasińska and Bystrowska 2016).
FAME were identified according to standards (Sigma–
Aldrich). The data were analyzed using ChemStation.
Results were expressed as relative percentages of the sum of
saturated (SFA), monounsaturated (MUFA), n-3 and n-6 FA.
LC-MS/MS conditions
Liquid chromatography was performed using an Agilent 1100
LC system (Agilent Technologies, Waldbronn, Germany).
Chromatographic separation was carried out with a Thermo
Scientific BDS HYPERSIL C18 column (100 × 3 mm I.D.,
3 μm particle size). The advance column, with its pre-column
(100 × 3 mm I.D., 3 μm particle size), was set at 40 °C with a
mobile phase flow rate of 0.3 mL/min. The gradient elution
mobile phases consisted of formic acid (0.02 mol/L) in aceto-
nitrile and formic acid (0.02 mol/L) in water. MS/MS analyzes
were performed on an Applied Biosystems MDS Sciex
(Concord, Ontario, Canada) API 2000 triple quadruple mass
spectrometer equipped with an electrospray ionization (ESI)
interface. ESI ionization was performed in positive ionization
mode. The multiple reaction monitoring (MRM) mode of the
dominant product ion for each ECBs was used. A comparison
of the paired ion (precursor and product ion m/z values) and LC
retention times with standards served to confirm the identifica-
tion of ECBs in the samples. Arachidonoyl ethanolamine
(AEA), AEA-d4, 2-ar iachonoylglycerol (2-AG),
eicosapentaenoyl ethanolamide (EPEA), EPEA-d4,
docosahexaenoyl ethanolamide (DHEA), DHEA-d4 and
nervonoyl ethanolamide (NEA) standards were purchased from
Cayman Chemical. An ion pair was 348 > 62 for AEA, 379 >
269 for 2-AG, 346 > 62 for EPEA, 372 > 62 for DHEA, 409 >
62 for NEA, 350 > 62 for EPEA-d4 and 376 > 66 for DHEA-
d4. Data acquisition and processing were performed using
Applied Biosystems Analyst version 1.4.2 software as de-
scribed previously (Gdula-Argasińska and Bystrowska 2016).
Statistics
All data are presented as means ± standard deviation (SD) or
medians and lower (Q25) and upper (Q75) quartiles. Normal
distribution of variables was checked using the Levene test.
Differences between study groups were determined using the
one-way ANOVA and Scheffe post hoc test, or Kruskal-Wallis
test if normality was not observed. Analysis of similarities
between content of the FA in CSF of studied groups was
performed using clustering methods to identify homogenous
groups of cases. Ward’s method with Euclidean distance ma-
trix was used to join objects into clusters such that the variance
within a cluster is minimized and to maximize the significance
of differences between clusters. Calculations were performed
using STATISTICA 13 (StatSoft Inc., Tulsa, OK, USA), and
statistical significance was defined as p ≤ 0.05.
Results
Markers of inflammation
Biochemical tests show significant differences between the
analyzed groups in the areas of CRP, WBC and CSF param-
eters. Patients with BM were characterized by the highest
values of markers of inflammation and lowering of glucose
in CSF. In the group of people with VM the markers of in-
flammation were slightly raised, and the glucose concentra-
tion in CSF was normal. Patients in the control group, as
predicted, were characterized by correct values of the param-
eters analyzed (Table 1).
Fatty acids content in CSF
FA composition in patients with neuroinfections and controls
are shown in Table 2. The saturated fatty acids (SFA) index in
CSF from VM patients (30.7%) was statistically lower than in
BM patients (35.01%), and also when compared to control
(39.14%). The monounsaturated fatty acid (MUFA) index in
CSF from controls was significantly higher (35.51%) than
both BM (24.52%) and VM (26.46%). We noticed changes
among n-3 and n-6 FA. Total n-3 FA were significantly de-
creased, and total n-6 FA were significantly increased in the
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CSF of patients with meningitis compared to healthy persons.
The CSF n-3/n-6 ratio was significantly decreased (more than
three-fold) in meningitis patients compared to the control
group (Table 2). There was no significant difference in FA
between BM and VM groups. The general trend of changes
in both groups with neuroinfection was both the same and
with similar intensity. We did not show statistically significant
differences between the BM and VM groups in the n-3 FA, n-
6 FA and n-3/n-6 ratio. An increase in monounsaturated and
polyunsaturated n-3 long-chain FA in the CSF obtained from
patients with neuroinfection was observed. In patients with
VM, the amount of linoleic acid increased more than 2.5
times, while in patients with BM there was statistically signif-
icant increase (three times) in the content of docosahexaenoic
acid (DHA, C22: 6 n-3) in CSF.
To determine the covariant behavior of the measured vari-
ables, we analyzed such variables to identify which one best
discriminates the FA profile in CSF from healthy people and
patients with BM and VM (Fig. 1a–c). Variables were sepa-
rated into three unique clusters. In healthy patients, CSF clus-
ter 1 consisted of SFA (C8:0, C10:0, C12:0, C14:0) and C16:1
as well as C18:3 n-3, EPA and C18:2 n-6 and arachidonic acid
(AA, C20:4 n-6). Cluster 2 consisted of a long chain ofMUFA
(C22:1 and C24:1), trans FA (C18:1 t, C18:2 t), C24:0, DHA
and n-6 FA (18:3 n-6, 20:3 n-6). In contrast, variants 16:0,
18:0, and 18:1 grouped further away (Fig. 1a).
In patients with BM, in contrast to the control, grouping of
n-3 FA in the first cluster consisted of the following variants:
18:2 n-6, 18:3 n-3, EPA, DHA and saturated fatty acids C8:0,
C12:0, C14:0 as well as long chain monounsaturated FA. n-6
and trans FA variants dominated in the second cluster (C18:3
n-6, C20:2 n-6, C20:3 n-6, AA and C22:6 n-6. In cluster 3, we
noted grouping of C18:0 and C18:1 FA (Fig. 1b). In CSF from
patients with VM in the cluster 1 long chain FAwere present
(C20:3 n-3, C22:1, C24:1, C24:0, C22:6 n-6, C20:1) as well
as saturated FA (C8:0 and C12:0). Cluster 2 consists of SFA
(C10:0, C14:0), MUFA (C14:1, C16:1), C18:3 n-3 as well as
n-6 FA (C18:2 n-6, C20:3 n-6 and AA). In the cluster 3 the
following FAwere present: C16:0, C18:0, C18:1 and n-6 FA
(C18:3 n-6, C22:6 n-6) (Fig. 1 c).
Endocannabinoids content
Arachidonoyl ethanloamide and 2-ariachonoylglycerol was
not detected in CSF of all groups. Statistically the highest
concentration of EPEA (1.65 pg/mL), DHEA (655 pg/mL)
and NEA (3.09 ng/mL) were detected in CSF from VM pa-
tients when compared to control (Table 3). In the samples
from BM patients the ECB concentrations were lower than
in VM, but significant differences were observed only for
DHEA content (Table 3).
Discussion
In our study for the first time we showed significant changes
in the composition of fatty acids and endocannabinoids in the
course of neuroinfections of various etiologies. Until now, the
assessment of FA composition in CSF has been evaluated in
few studies, but the evaluation has never been carried out in
the course of neuroinfection. It was not known whether FA as
well as ECB in the CNS during infection play a similar role as
Table 1 Comparison of WBC, CRP and biochemical CSF parameters in the analyzed groups. Medians, lower and upper quartiles, n = 19
Parameter BM (group 1) VM (group 2) Control group (group 3) p
Median Q25-Q75 Median Q25-Q75 Median Q25-Q75
CRP [mg/L] 78 34–160 3.2 2–26 1.2 1–5 1vs2 = 0.000
1vs3 = 0.04
2vs3 = 0.000
WBC [×103/μL] 11.4 7.7–22.1 7.8 5.4–9 5.2 4.7–6.3 1vs2 = 0.005
1vs3 = 0.01
2vs3 = 0.000
CSF pleocytosis [count /μL] 1150 237–1600 62 18–150 2 1–4 1vs2 = 0.000
1vs3 = 0.000
2vs3 = 0.000
CSF protein [g/L] 3.2 1.2–5.2 0.6 0.5–0.8 0.4 0.3–0.6 1vs2 = 0.000
1vs3 = 0.005
2vs3 = 0.000
CSF glucose [mmol/L] 1.6 0–2.1 2.7 2.5–3.3 3.1 2.9–3.4 1vs2 = 0.000
1vs3 = 0.02
2vs3 = 0.000
BM bacterial meningitis, CRP C-reactive protein, CSF cerebro-spinal fluid, Q25 lower quartile, Q75 upper quartile, VM viral meningitis, WBC white
blood cells
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has been shown during infection in other parts of the body.
Our study again demonstrates the important role of FA and
their derivatives in the course of central nervous system pa-
thology. There are hypothetically two mechanisms which
could explain the changes in CSF composition observed in
our study.
Fatty acids contribute to the systemic and local
immune response
Polyunsaturated fatty acids are essential for brain homeostasis
and functions and are the main components of neuronal mem-
branes (Kong et al. 2011; Calder 2016). FA metabolism may
be an important mechanism underlying rapid neuroinflamma-
tion in pathologic processes such as neuroinfections.
The first mechanism would result from the fact that FA
contribute to the systemic and local immune response trig-
gered by pathogens that reached the CNS, as such changes
in FA as well as in ECB in CSF would be a reflection of the
ongoing inflammatory process in the CNS. In our study, we
showed a significant increase in n-6 FA in the course of
neuroinfection compared to the control group, this effect oc-
curred regardless of etiology. The strongest increase of n-6
FA, mainly C18:3 (gamma-linolenic acid, GLA), C20:2
(dihomo-gamma linolenic acid, DGLA), C20:3, C20:4 (ara-
chidonic acid, AA) and C22:2 (adrenic acid) was observed in
CSF from VM patients. DGLA, which is product of GLA
conversion by elongase 5 (ELOVL5), can be enzymatically
transformed to several metabolites with anti-inflammatory
properties (Sergeant et al. 2016). DGLA may be also a pre-
cursor of arachidonic acid (AA). As a result of AA enzymatic
oxidation, prostaglandins, leukotrienes, and lipoxins are
formed and may generally promote inflammation (Serhan
and Petasis 2011; Norris and Dennis 2014). Results obtained
in our study suggest that n-6 FA significantly attenuate in an
neuro-inflammatory responses.We also observed cluster char-
acteristic grouping of n-6 fatty acids in patients with BM and
VM. Similar to the changes in the n-6 FA in both
neuroinfection groups, there was a decrease in n-3 FA in
CSF in relation to healthy people. The strongest decrease
was observed in the precursor for n-3 FA: linolenic acid
(ALA, C18:3 n- 3) and in eicosapentaenoic acid (EPA,
C20:5 n-3). The deficit of n-3 FA in cerebrospinal fluid from
patiens with neuroinfections when compared to the control
was seen also after cluster analysis. ALA is a precursor for
n-3 series, including EPA or DHA, they show strong anti-
inflammatory effects (Gdula-Argasińska et al. 2016;
Wysoczański et al. 2016). Inflammation is an important ele-
ment of the body’s fight with infection, however, the body
also has effective mechanisms to quench the inflammatory
reaction. The lack of such a mechanism and an excessive
pro-inflammatory reaction would pose a significant threat to
the homeostasis of the body. The process of resolution of
inflammation itself does not have an immunosuppressive
character, as several pro-resolving mediators increase survival
from different infections. n-3 FA are one of the elements of
such extinguishing, hence the observation in our study. A
reflection of the changes in the n-6 and n-3 FA is more than
three-fold reduction of n-3/n-6 ratio, this effect was observed
for both types of neuroinfections studied.
The changed FA profile in CSF appears to be caused by the
synthesis of lipid mediators, including eicosanoids, generated
during inflammation by microglia and astrocyte cells. These
changes may also be related to the biosynthesis of
endocannabinoids, as well as being the result of a diversified
expression of genes involved in the synthesis, elongation and
Table 2 Fatty acid content [%] in cerebrospinal fluid from healthy,
bacterial and viral meningitis. Means ± SD; n = 19
FA BM VM Control
C8:0 2.28# ± 0.36 1.15* ±0.26 1.64 ± 0.26
C10:0 5.43# ± 1.14 3.51#,* ± 0.83 1.70 ± 0.83
C12:0 2.72# ± 0.71 1.26#,* ± 0.51 5.67 ± 0.51
C14:0 2.10 ± 0.46 1.94 ± 0.34 2.74 ± 0.34
C16:0 8.27# ± 1.27 9.72 ± 0.92 12.28 ± 0.92
C18:0 13.31 ± 1.94 12.66# ± 1.41 17.96 ± 1.41
C24:0 0.91# ± 0.38 0.52* ±0.27 0.30 ± 0.27
SFA 35.01 ± 6.27 30.70#,* ± 4.55 39.14 ± 4.55
C14:1n-5 1.95# ± 0.40 2.20# ± 0.29 0.16 ± 0.29
C16:1n-7 1.43# ± 0.39 1.99* ±0.29 2.18 ± 0.29
C18:1 n-9 19.07# ± 2.80 21.35# ± 2.03 32.75 ± 2.03
C20:1n-9 1.07# ± 0.36 0.52#,* ± 0.26 0.26 ± 0.00
C22:1n-9 0.34# ± 0.11 0.19#,* ± 0.08 0.08 ± 0.00
C24:1n-9 0.66# ± 0.12 0.21#,* ± 0.09 0.09 ± 0.00
MUFA 24.52# ± 4.17 26.46# ± 3.03 35.51 ± 2.61
C18:1n-9 t 3.33# ± 1.15 0.72* ±0.84 0.72 ± 0.84
C18:2n-6 t 0.51 ± 0.25 0.47# ± 0.18 0.78 ± 0.18
trans 3.84# ± 1.41 1.19 ± 1.02 1.50 ± 1.02
C18:2n-6 2.63# ± 0.71 4.34* ±0.52 5.03 ± 0.52
C18:3n-6 5.00# ± 2.89 12.40#,* ± 2.09 2.09 ± 0.26
C20:2n-6 3.22# ± 1.32 2.85# ± 0.96 0.96 ± 0.05
C20:3n-6 4.58# ± 1.21 2.96#,* ± 0.88 0.60 ± 0.88
C20:4n-6 5.51 ± 1.26 5.38 ± 0.92 4.99 ± 0.92
C22:2n-6 9.51# ± 2.60 8.07# ± 1.89 0.11 ± 1.89
n-6 30.46# ± 10.00 35.99# ± 7.25 13.78 ± 4.52
C18:3n-3 2.02# ± 0.72 2.00# ± 0.52 3.32 ± 0.52
C20:3n-3 0.80 ± 0.44 0.79 ± 0.32 0.99 ± 0.32
C20:5n-3 2.30# ± 0.66 2.52# ± 0.48 5.42 ± 0.48
C22:6n-3 1.04# ± 0.37 0.36* ±0.27 0.34 ± 0.27
n-3 6.16# ± 2.20 5.67# ± 1.60 10.07 ± 1.60
n-3/n-6 0.20# ± 0.02 0.22# ± 0.06 0.73 ± 0.15
BM bacterial meningitis, FA fatty acids, MUFA monounsaturated fatty
acids, SFA saturated fatty acids, VM viral meningitis; #p < 0.01 vs. con-
trol, *p < 0.01 vs. BM
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desaturation of FA during the inflammatory process (Serhan
and Petasis 2011; Gdula-Argasińska et al. 2016).
Endocannabinoids are lipid mediators which play an impor-
tant physiological role via cannabinoid receptor (CB1 and
CB2) activation and signalling. Both DHEA and EPEA have
anti-inflammatory properties and have been detected in both
the brain and retina (Gdula-Argasińska and Bystrowska 2016;
Wysoczański et al. 2016; McDougle et al. 2017). In our study
we observed the highest content of DHAE, EPEA and NEA in
the CSF of patients with VM. In samples from BM patients
the ECB level was lower. ECB synthesis during
neuroinfection is probably one of the mechanisms by which
inflammation is resolved.
The dense clustering of the different cell types during in-
flammation presents a unique situation for lipid handling. In
contrast to the synthesis of protein mediators (cytokines), lipid
mediators can be produced along enzyme pathways that in-
volve multiple cells, including microglia, in a process known
as trans-cellular biosynthesis (Serhan and Petasis 2011; Norris
and Dennis 2014; Johnson 2015). The inflamed tissue becomes
a specialized organ for lipid metabolism, producing the types
and amounts of lipid mediators needed to promote or resolve
inflammation. However, the higher content of long-chain
MUFA and PUFA in CSF obtained from patients with BM
and VM may be correlated with higher expression of stearoyl-
coenzyme A desaturase (SCD1) as well as elongases (Gdula-
Argasińska and Bystrowska 2016; Sergeant et al. 2016).
Changes in fatty acids in CSF as a consequents of BBB
permeability
The secondmechanismwhichmay explain the results observed
in our study is passive FA penetration from the plasma through
the damaged BBB as a result of the neuroinfection. Under
physiological conditions, the BBB provides effective protection
of the nervous system from external factors. The transcellular
transport across the BBB involves diffusion and active transport
with the use of carrier membrane proteins. The diffusion
process transports mainly small-molecule nutrients and fat-
soluble substances. Peptides and regulatory proteins as well as
protein hormones penetrate the BBB via active transport with
protein carriers. The transported substances are not transmitted
directly to neurons, but to glial pellets. The astrocyte protru-
sions cover about 90% of the surface of the capillary walls.
These cells constitute the second component, also crucial for
the effectiveness of the physical barrier. They are links between
the capillary wall and neurons (Ballabh et al. 2004; Nakagawa
et al. 2009). The exact characteristics of the BBB are presented
in review by Sorge et al. (van Sorge and Doran 2012).
CSF is a secretion of the choroid plexuses located in the
wall of the cerebral ventricles and periventricular organs. The
transport of substances from the blood to CSF is very selec-
tive, because glial cells (tanycetes) adhere to the endothelium
and functions to assist in taking certain substances (eg. hor-
mones) from the blood and transferring them to the CSF, as
well as in the opposite direction (Lossinsky and Shivers
2004). BBB permeability disorders have been described in
various neurological diseases, including inflammatory, infec-
tious, neurodegenerative and neoplastic diseases. A special
group of diseases that change the physiological properties of
BBB include neuroinfections. Under physiological condi-
tions, there is little infiltration of T-lymphocytes and mono-
cytes through the BBB, the situation changes during infec-
tious processes involving the nervous system, during which
an increased transmission of cells of the immune system
across the BBB is observed (Weiss et al. 2009). Impaired
integrity of the BBB is one of the key factors in BM patho-
genesis and is also extremely important for the development
of VM. This may be due to the toxic effect of pathogens, their
products or through the ability to interact with BBB structures,
mainly AJs and TJs. For example, group B Streptococcus
(GBS) and Streptococcus pneumoniae directly affect BBB
by producing spore-forming toxins (Nizet et al. 1997; Zysk
et al. 2001; Lembo et al. 2010). As GBS produce more toxins,
they are more apt to cause BM (Doran et al. 2003). Many
viruses damage the cytoskeletal actin during their life cycle
(Taylor et al. 2011). In addition, in the course of induced
neuroinfections with various etiologies of the immune reac-
tion, cytokines/chemokines molecules are produced that may
interfere with the functioning of the BBB, which in turn facil-
itates the development of neuroinfections and is associated
Fig. 1 Cluster analysis of the FA profile in CSF from healthy people (a)
and from patients with bacterial (b) and viral malignance (c). Data were
segregated into three unique clusters of variables by hierarchical cluster
analysis
Table 3 Endocannabinoids
content in CSF of BM, VM
patients and healthy control.
Medians, lower and upper
quartiles, n = 19
ECB BM (group 1) VM (group 2) Control group (group 3) p
Median Q25-Q75 Median Q25-Q75 Median Q25-Q75
EPEA [pg/mL] 0.5 0.3–1.9 1.6 0.5–4.3 0.4 0.3–0.5 2vs3 = 0.01
DHEA [pg/mL] 139 109–168 655 169–840 130 100–144 1vs2 = 0.002
2vs3 = 0.000
NEA [ng/mL] 1.5 0.8–3.5 3.1 1.5–4.1 1.6 1.0–2.2 2vs3 = 0.022
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with worsening the prognosis of such patients (van Sorge and
Doran 2012). An example is the increase in systemic expres-
sion of TNF-α, which translates into an increase in BBB per-
meability (Sharief et al. 1992). Thus, with the BBB’s excess
permeability increasing in the course of neuroinfection, FA
could passively pass into CSF.
In our study, there was no significant difference in majority
FA between BM and VM groups. But the general trend of
changes in both groups with neuroinfection was both the same
and with similar intensity. Significant differences were dem-
onstrated for LA, GLA and DHA content.
In conclusion, FA are an important element of the inflam-
matory reaction in the course of neuroinfection, as demon-
strated by the significant increase in n-6 FA and decrease in
n-3 FA as well as significant increase of EPEA, DHEA in CSF
during neuroinfections of various etiology in relation to
healthy people. A limit of our study was that patients were
not supplemented with PUFA, therefore it seems necessary to
consider this area in the future.
The process of resolution of inflammation, so important to
the health of the patient, is still not fully understood.
Therefore, the description of fatty acid impaired metabolism
in the course of neuroinfection appears to be an important
issue. It may allow, inter alia, to develop new pharmacological
strategies, therapeutic aims and modern drugs, essential in the
fight against neuroinfections. It appears that fatty acids and
their metabolites, which are ligands for peroxisome
proliferator receptors (PPARs) and nuclear factor kappa B
(NF-ĸB) transcription factors (Gdula-Argasińska and
Bystrowska 2016; Qasem et al. 2018) may be used as
nutraceuticals in the regulation of brain immune response.
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